Cue Biopharma, Inc.

NASDAQ:CUE

Biotechnology

Healthcare
$14.10 +1.42%

+$0.38 today

Market cap
$102.43M
Beta
2.53
P/E (TTM)
-6.7
EPS (TTM)
-$4.06
52W Low $4.98High $41.42

Volume 0.21M

Average 0.74M

Returns on capital

Cue Biopharma, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-100.6%

avg -88.4%

ROIC

-86.6%

avg -71.5%

ROA

-63.0%

avg -61.2%

Analysis

ROA is currently the strongest return metric at -63.0% versus its period average of -61.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

James Ahlers

Chief Financial OfficerUSD 577.28K62——

Lucinda Warren

Principal Accounting Officer & Chief Business OfficerUSD 470.95K57250.00K9.51%

Colin G. Sandercock

Senior Vice President of Intellectual PropertyUSD 449.64K69——

Shao-Lee Lin

President, CEO & DirectorUSD 434.2K59694.91K26.44%

Rodolfo J. Chaparro

Co-FounderUSD 316.63K53——

Ronald D. Seidel

Co-FounderUSD 316.63K50——

Agnes Lee

Chief Officer of Public & Investor Relations————

Sumita Ray

Chief Legal & Compliance Officer and Corporate Secretary—52116.70K4.44%

Steven C. Almo

Co-Founder and Chairman of Scientific & Clinical Advisory Board—65——

Daniel G. Baker

Interim Chief Development Officer—76100.00K3.81%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 12, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

7

$599,821.17

Sells

15

$2.43M

Net Transaction Value

−$1.83M

Net selling

Most Active

Lin Shao-Lee

9 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 12, 26

Meluzio Michael Vincent

Direct

Sell$32.1K
Oct 12, 26

Ray Sumita

Direct

Sell$51.7K
Oct 12, 26

Lin Shao-Lee

Direct

Sell$275K
Oct 12, 26

Lin Shao-Lee

Direct

Sell$30.5K
Aug 13, 26

Meluzio Michael Vincent

Direct

Sell$124.6K
Aug 13, 26

Ray Sumita

Direct

Sell$195.5K
Aug 13, 26

Ray Sumita

Direct

Sell$124.5
Aug 13, 26

Meluzio Michael Vincent

Direct

Sell$44.6K
Aug 13, 26

Meluzio Michael Vincent

Direct

Sell$93.4
Aug 13, 26

Lin Shao-Lee

Direct

Sell$147.5K

1–10 of 22

Summary

Insiders reported 7 buys worth $599,821.17 and 15 sells worth $2.43M over the last 12 months. That adds up to net selling of $1.83M. Lin Shao-Lee was the most active insider with 9 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+180.5%
-22.3% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at +180.5% over three years. Forward estimates point to Revenue at -22.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Cue Biopharma, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CUE's management, answered from reported figures.

Who manages CUE?

Cue Biopharma, Inc. (CUE) lists 10 active executives. The top listed executive is Rodolfo J. Chaparro, Co-Founder.

Are CUE insiders buying or selling?

Recent insider activity shows net buying of $43.67M.